Salspera Inc. (TKVA)
| Market Cap | 938.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.73M |
| Shares Out | 62.54M |
| EPS (ttm) | -0.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About TKVA
Salspera is focused on the development and commercialization of a new class of immunotherapeutics for the treatment of solid tumors. This new class of drugs, sometimes referred to as “live biopharmaceuticals” are genetically modified biological agents which have the capability of expressing select anti-tumoral agents within the tumor’s microenvironment. Our lead program, Saltikva, is an attenuated strain of Salmonella Typhimurium that is non-toxic and orally administered. Saltikva is being developed for the treatment of multiple oncology indica... [Read more]
Financial Performance
Financial StatementsNews
Salspera IPO Registration Document (S-1)
Salspera has filed to go public with an IPO on the NASDAQ
Immuno-oncology biotech Salspera files for a US IPO
Salspera, a clinical-stage cancer biotech developing live biopharmaceuticals to stimulate an immune response, filed on Monday with the SEC for an initial public offering. The company filed with an $85...